Short answer
DiaMedica Therapeutics Inc. (DMAC) filed an 8-K current report with the SEC on May 21, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). All seven incumbent directors re-elected, preserving board continuity through the next annual meeting.
DiaMedica Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- All seven incumbent directors re-elected, preserving board continuity through the next annual meeting
- Baker Tilly US, LLP ratified as independent auditor for fiscal 2026, with shareholders authorizing board-set remuneration
- Executive compensation approved on an advisory basis, with 9,928,381 votes for versus 271,093 against
- Incentive plan expanded by 3,500,000 shares, increasing potential equity dilution and compensation capacity
- Daniel O’Connor faced the closest director vote, with 5,217,758 votes for and 5,130,879 withheld
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other DiaMedica Therapeutics Inc. 8-K filings
Get the next DMAC 8-K as it lands
Follow DMAC for push alerts, or ask the research agent what this filing means.